431 related articles for article (PubMed ID: 7908969)
1. Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state.
Acartürk F; Imai T; Saito H; Ishikawa M; Otagiri M
J Pharm Pharmacol; 1993 Dec; 45(12):1028-32. PubMed ID: 7908969
[TBL] [Abstract][Full Text] [Related]
2. Inclusion complex of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) with heptakis(2,6-di-O-methyl)-beta-cyclodextrin: interaction and dissolution properties.
Yamada T; Imai T; Ouchi K; Otagiri M; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1264-9. PubMed ID: 10993223
[TBL] [Abstract][Full Text] [Related]
3. Encapsulation and Stabilization of α-Lipoic Acid in Cyclodextrin Inclusion Complex Electrospun Nanofibers: Antioxidant and Fast-Dissolving α-Lipoic Acid/Cyclodextrin Nanofibrous Webs.
Celebioglu A; Uyar T
J Agric Food Chem; 2019 Nov; 67(47):13093-13107. PubMed ID: 31693349
[TBL] [Abstract][Full Text] [Related]
4. Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-alpha- and -beta-cyclodextrins.
Kimura K; Hirayama F; Arima H; Uekama K
Pharm Res; 1999 Nov; 16(11):1729-34. PubMed ID: 10571279
[TBL] [Abstract][Full Text] [Related]
5. Study of the interaction of clobazam with cyclodextrins in solution and in the solid state.
Nakai Y; el-Said Aboutaleb A; Yamamoto K; Saleh SI; Ahmed MO
Chem Pharm Bull (Tokyo); 1990 Mar; 38(3):728-32. PubMed ID: 2347015
[TBL] [Abstract][Full Text] [Related]
6. Heptakis(2,6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: A water-soluble cyclodextrin derivative with low hemolytic activity.
Hirayama F; Mieda S; Miyamoto Y; Arima H; Uekama K
J Pharm Sci; 1999 Oct; 88(10):970-5. PubMed ID: 10514341
[TBL] [Abstract][Full Text] [Related]
7. Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with beta-cyclodextrin.
Anzai K; Mizoguchi J; Yanagi T; Hirayama F; Arima H; Uekama K
Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1466-70. PubMed ID: 17917290
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the antiinflammatory effect of ethyl 4-biphenylyl acetate in ointment by beta-cyclodextrin derivatives: increased absorption and localized activation of the prodrug in rats.
Arima H; Adachi H; Irie T; Uekama K; Pitha J
Pharm Res; 1990 Nov; 7(11):1152-6. PubMed ID: 2293214
[TBL] [Abstract][Full Text] [Related]
9. Interaction of heptakis (2,3,6-tri-O-methyl)-beta-cyclodextrin with cholesterol in aqueous solution.
Nishijo J; Moriyama S; Shiota S; Kamigauchi M; Sugiura M
Chem Pharm Bull (Tokyo); 2004 Dec; 52(12):1405-10. PubMed ID: 15577234
[TBL] [Abstract][Full Text] [Related]
10. Improvement of dissolution and suppository release characteristics of flurbiprofen by inclusion complexation with heptakis(2,6-di-O-methyl)-beta-cyclodextrin.
Uekama K; Imai T; Maeda T; Irie T; Hirayama F; Otagiri M
J Pharm Sci; 1985 Aug; 74(8):841-5. PubMed ID: 4032267
[TBL] [Abstract][Full Text] [Related]
11. Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin.
Miyake K; Arima H; Hirayama F; Yamamoto M; Horikawa T; Sumiyoshi H; Noda S; Uekama K
Pharm Dev Technol; 2000; 5(3):399-407. PubMed ID: 10934740
[TBL] [Abstract][Full Text] [Related]
12. The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ-cyclodextrin and its dissolution characteristics.
Igami K; Ozawa M; Inoue S; Iohara D; Miyazaki T; Shinoda M; Anraku M; Hirayama F; Uekama K
J Pharm Pharmacol; 2016 May; 68(5):646-54. PubMed ID: 26255976
[TBL] [Abstract][Full Text] [Related]
13. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
Kim JH; Lee SK; Ki MH; Choi WK; Ahn SK; Shin HJ; Hong CI
Int J Pharm; 2004 Mar; 272(1-2):79-89. PubMed ID: 15019071
[TBL] [Abstract][Full Text] [Related]
14. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution.
Miyake K; Hirayama F; Uekama K
J Pharm Sci; 1999 Jan; 88(1):39-45. PubMed ID: 9874700
[TBL] [Abstract][Full Text] [Related]
15. Physico-chemical characterization of disoxaril-dimethyl-beta-cyclodextrin inclusion complex and in vitro permeation studies.
Ventura CA; Giannone I; Musumeci T; Pignatello R; Ragni L; Landolfi C; Milanese C; Paolino D; Puglisi G
Eur J Med Chem; 2006 Feb; 41(2):233-40. PubMed ID: 16387393
[TBL] [Abstract][Full Text] [Related]
16. Improvement of dissolution characteristics of psoralen by cyclodextrins complexation.
Vincieri FF; Mazzi G; Mulinacci N; Bambagiotti-Alberti M; Dall' Acqua F; Vedaldi D
Farmaco; 1995; 50(7-8):543-7. PubMed ID: 7669193
[TBL] [Abstract][Full Text] [Related]
17. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
18. Preparation and preliminary evaluation of novel beta-cyclodextrin/IUDR prodrug formulations.
Wiebe LI; Yang XH; Singh S; Diakur J
J Pharm Pharm Sci; 2008 Jun; 11(2):32s-43s. PubMed ID: 19203469
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
J Pharm Sci; 2001 Jun; 90(6):690-701. PubMed ID: 11357172
[TBL] [Abstract][Full Text] [Related]
20. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
